Barricade Therapeutics logo
Barricade Therapeutics logo

Barricade Therapeutics

barricadetherapeutics.com
barricadetherapeutics.com • HQ: Fort Worth, United States • Convertible Note 2026 • 51-200 employees • Founded 2017 • Startup
HQ: Fort Worth, United States • Convertible Note 2026 • 51-200 employees • Founded 2017 • Startup
Actively hiring
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$100k
1 round on record
Latest round
$100k
Convertible Note · May 2026 · 4 mo ago
Team
51-200
employees, estimated range
Backers
1
TechFW | Tech Fort Worth
The money's age
Fresh money
4 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 27 Raised a round Convertible Note $100k · SEC Form D 2017 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note May 2026 $100k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Barricade Therapeutics Corp SEC Form D
Founders and leadersfrom filings, registers and the company's site
Neil ThaparExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
TechFW | Tech Fort Worth fund
Investors in similar startupsfunds that back the companies most like this one
Draper Associates
backs Cloverleaf Bio, Hum Capital
ARCH Venture Partners
backs Akamis Bio
Greycroft
backs Hum Capital
Entrée Capital
backs re:cap
Felix Capital
backs re:cap
Project A
backs re:cap
Similar startupsby what they do, their industry and backers
Akamis BioSeries A $60M · 21 mo ago • 51-200 employees
Transforming the future of colorectal cancer therapy. Akamis Bio is working to advance the standard of care in colorectal cancer by…
MiWendoFounded 2019 • 201-500 employees
MiWEndo Solutions enhances early detection of colorectal cancer with innovative technology. We transform colonoscopies to provide more…
Hum CapitalSeries A $9M · 5 yr ago • 11-50 employees
Access $1M–$50M in non-dilutive growth capital for expansion, acquisitions, working capital, refinancing and other strategic business needs.
re:capVenture round $14.6M · 2 yr ago • Founded 2021 • 201-500 employees • 1 role
re:cap is a Berlin financial technology company founded in 2021 that provides non-dilutive funding against recurring revenue. Its platform…
Quercis Pharma AG
Quercis Pharma develops Kinisoquin™, a first-in-class oral PDI inhibitor in Phase 3 for the prevention of cancer-associated thrombosis…
Cloverleaf BioSeed $33M · 1 mo ago • Founded 2023 • 51-200 employees • 3 roles
Cloverleaf Bio is an early-stage therapeutics company developing a new class of engineered RNA therapeutics for cancer therapy. It hires…

Overview

A New Era in Colorectal Cancer Therapy. Backed by over $17M in non-dilutive funding, Barricade is advancing a first-in-class oral therapy designed to change how colorectal cancer is treated.

People

Neil Thapar
Executive Officer
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Fort Worth United States
HQ
Barricade Therapeutics
50-200 est. staff
1120 South Freeway, Suite 103, Fort Worth, TX 76104
company site

Financials

Total raised
$100k
Latest round
Convertible Note
Funding rounds
1
Funding rounds
Round Announced Amount
Convertible Note 2026 $100k Details